Smoflipid® Approved by FDA and Available in US

Fresenius Kabi has informed ASPEN that a four-oil IV fat emulsion (IVFE) known as Smoflipid® has been approved by the FDA and is now available in the US for adult patients. This IVFE product has been used for many years in other global markets and contains soybean oil, medium chain triglycerides, olive oil, and fish oil. Information on this product is included in the package insert on the FDA website. For any questions about this new product including dosing details, contact: Fresenius Kabi Vigilance and Medical Affairs Phone:  1-800-551-7176 or email.

ASPEN journals have published many articles on this product and several recent good reviews are available:

Home Parenteral Nutrition: Fat Emulsions and Potential Complications

Clinical Trials and Meta-analyses Include:
Wu MH, Wang MY, Yang CY, Kuo ML, Lin MT. Randomized clinical trial of new intravenous lipid (SMOFlipid 20%) versus medium-chain triglycerides/long-chain triglycerides in adult patients undergoing gastrointestinal surgery.JPEN J Parenter Enteral Nutr. 2014;38(7):800-808.

Ma CJ, Sun LC, Chen FM, et al. A double-blind randomized study comparing the efficacy and safety of a composite vs a conventional intravenous fat emulsion in postsurgical gastrointestinal tumor patients.Nutr Clin Pract. 2012;27(3):410-415.

Antebi H, Mansoor O, Ferrier C, et al. Liver function and plasma antioxidant status in intensive care unit patients requiring total parenteral nutrition: comparison of 2 fat emulsions.J Parenter Enteral Nutr. 2004;28(3):142-148.

Manzanares W, Dhaliwal R, Jurewitsch B, et al. Parenteral fish oil lipid emulsions in the critically ill: a systematic review and meta-analysis.JPEN J Parenter Enteral Nutr. 2014;38(1):20-28.

Chen B, Zhou Y, Yang P, Wan HW, Wu XT. Safety and efficacy of fish oil-enriched parenteral nutrition regimen on postoperative patients undergoing major abdominal surgery: a meta-analysis of randomized controlled trials.JPEN J Parenter Enteral Nutr. 2010;34(4):387-394.